European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study
Authors
Michelino De Laurentiis (ORCID: https://orcid.org/0000-0001-9009-1572)
Markus Lucerna
José Á. García-Sáenz (ORCID: https://orcid.org/0000-0001-6880-0301)
European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study
Michelino De Laurentiis, Markus Lucerna, José Á. García-Sáenz, Giampaolo Bianchini et al.
Citations
1 citations
Journal
Frontiers in Oncology
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
1.05
article
European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study
Michelino De Laurentiis, Markus Lucerna, José Á. García-Sáenz, Giampaolo Bianchini, Arthur Allignol, Amanda Logue, Cristina Saura, Sabine Stamenitis, Hans Wildiers
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in OncologyVol. 15
Institutions
Hebron University (PS), Vita-Salute San Raffaele University (IT), Daiichi Sankyo (Germany) (DE), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), AstraZeneca (France) (FR), IRCCS Ospedale San Raffaele (IT), Daiichi-Sankyo (South Korea) (KR), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), KU Leuven (BE)
Funders
Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Helsinn, Jazz Pharmaceuticals, Les Laboratories Pierre Fabre, Puma Biotechnology, Seagen, Università Campus Bio-Medico di Roma, Eisai, Istituto Oncologico Veneto, Menarini Group, Ipsen, Daiichi Sankyo Europe